Deloitte and Startup Vineti Team Up for Personalized Medicine
Vineti Inc. and Deloitte have struck a deal aimed at making complex cell- and gene-therapy procedures more transparent.
Drug developers are developing a growing number of cell and gene therapies. These treatments can be complex. New, CAR-T therapies for cancer, for example, involve harvesting a patient’s own immune cells, genetically modifying them and returning them to the patient.
San Francisco-based Vineti has raised just more than $47 million, from venture investors such as Canaan Partners and Section 32 since 2016, to provide drug companies and other clients with a cloud-based technology to manage that process of delivering cell and gene treatments. Vineti’s platform extends from the drug manufacturer to the health-care provider. Deloitte, meanwhile, has a platform to connect health-care providers and patients.
By working together, the two platforms can create an end-to-end solution that gives patients more visibility into the treatment being prepared for them.
